Osteoporosis and ankylosing spondylitis

Joint Bone Spine

Volumn 71, Issue 4, 2004, Pages 291-295

  El Maghraoui, Abdellah ^a  

^a MILITARY HOSPITAL MOHAMMED V   (Morocco)

Author keywords

Ankylosing spondylitis; Osteoporosis

Indexed keywords

CYTOKINE; GLUCOCORTICOID; INTERLEUKIN 1; INTERLEUKIN 6; NITRIC OXIDE; PAMIDRONIC ACID; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ANKYLOSING SPONDYLITIS; BONE DENSITY; BONE METABOLISM; BONE REMODELING; CHRONIC ARTHRITIS; DUAL ENERGY X RAY ABSORPTIOMETRY; HUMAN; INFLAMMATORY DISEASE; MEASUREMENT; METABOLIC DISORDER; MORBIDITY; MORTALITY; OSSIFICATION; OSTEOPENIA; OSTEOPOROSIS; REVIEW; VERTEBRA FRACTURE;

EID: 3843108009     PISSN: 1297319X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jbspin.2003.06.002     Document Type: Short Survey

References (46)

1. Sieper J., Braun J., Rudwaleit M., Boonen A., Zink A. Ankylosing spondylitis: an overview. Ann Rheum Dis. 61:(Suppl III):2002;8-18
2. El Maghraoui A., Bensabbah R., Bahiri R., Bezza A., Guédira N., Hajjaj-Hassouni N. Cervical spine involvement in ankylosing spondylitis. Clin Rheumatol. 22:2003;94-98
3. El Maghraoui A., Chaouir S., Tabache F., Abouzahir A., Bezza A., Ghafir D., et al. High resolution thoracic CT in ankylosing spondylitis. Ann Rheum Dis. 62:2003;185-186
4. Bezza A., El Maghraoui A., Ghadouane M., Tabache F., Abouzahir A., Abbar M., et al. Idiopathic retroperitoneal fibrosis and ankylosing spondylitis. A new case report. Jt Bone Spine. 69:2002;502-505
5. Reid D.M., Nicoll J.J., Kennedy N.S., Smith M.A., Tothill P., Nuki G. Bone mass in ankylosing spondylitis. J Rheumatol. 13:1986;932-935
6. Will R., Palmer R., Bhalla A.K., Ring F., Calin A. Osteoporosis in early ankylosing spondylitis. A primary pathological event? Lancet. ii:1989;1483-1485
7. Calin A. Osteoporosis and ankylosing spondylitis. Br J Rheumatol. 30:1991;318-319
8. Rubinstein H.M. Osteoporosis in ankylosing spondylitis. Br J Rheumatol. 30:1991;160
9. Lehtilen K. Mortality and causes of death in 398 patients admitted to hospital with ankylosing spondylitis. Ann Rheum Dis. 52:1993;174-176
10. Khan M.A., Lai J.-H., Chang D.-M., Liu H.-C. Recognizing and managing fractures in ankylosing spondylitis. J Musculoskelet Med. 1:1993;45-57
11. Hansen C.A., Shagrin J.W., Duncan H. Vertebral osteoporosis in ankylosing spondylitis. Clin Orthop. 74:1971;59-64
12. Raltson S.H., Urquhart G.D.K., Bzeski M., Sturrock R.D. Prevalence of vertebral compression fractures due to osteoporosis in ankylosing spondylitis. Br Med J. 300:1990;563-565
13. Donnelly S., Doyle D.V., Denton A., Rolfe J., McCloskey E.V., Spector T.D. Bone mineral density and vertebral compression fracture rates in ankylosing spondylitis. Ann Rheum Dis. 53:1994;117-121
14. Cooper C., Carbone L., Michet C.J., Atkinson E.J., O'Fallon W.M., Melton L.J. Fracture risk in patients with ankylosing spondylitis: a population based study. J Rheumatol. 21:1994;1877-1882
15. Devogelaer J.-P., Maldague B., Malghem J., Nagant de Deuxchaisnes C. Appendicular and vertebral bone mass in ankylosing spondylitis. Arthritis Rheum. 35:(9):1992;1062-1067
16. Bronson W.D., Walker S.E., Hillman L.S., Keisler D., Hoyt T., Allen S.H. Bone mineral density and biochemical markers of bone metabolism in ankylosing spondylitis. J Rheumatol. 25:1998;929-935
17. Mullaji A.B., Ho E.K.W. Bone mineral density in ankylosing spondylitis. DEXA comparison of control subjects with mild and advanced cases. J Bone Jt Surg. 76B:1994;660-665
18. El Maghraoui A., Borderie D., Edouard R., Roux C., Dougados M. Osteoporosis, body composition and bone turnover in ankylosing spondylitis. J Rheumatol. 26:1999;2205-2209
19. Toussirot E., Michel F., Wendling D. Bone density, ultrasound measurements and body composition in early ankylosing spondylitis. Rheumatology. 40:2001;882-888
20. El Maghraoui A., Chaouir S., Bezza A., Tabache F., Abouzahir A., Ghafir D., et al. Evaluation de la densité minérale osseuse au cours de la spondylarthrite ankylosante par tomodensitométrie quantitative. Rev Mar Rhum. 15:2003;129-133
21. Speden D.J., Calin A.I., Ring F.J., Bhalla A.K. Bone mineral density, calcaneal ultrasound, and bone turnover markers in women with ankylosing spondylitis. J Rheumatol. 29:2002;516-521
22. Wendling D., Dumoulin G. Spondylarthrite ankylosante et paramètres phosphocalciques. Rev Rhum. 58:1991;279-281
23. Franck H., Keck E. Serum osteocalcin and vitamin D metabolites in patients with ankylosing spondylitis. Ann Rheum Dis. 52:1993;343-346
24. Marhoffer W., Stracke H., Masoud H., Scheja M., Graef V., Bolten W. Evidence of impaired cartilage/bone turnover in patients with active ankylosing spondylitis. Ann Rheum Dis. 54:1995;556-559
25. MacDonald A.G., Birkinshaw G., Durham B., Bucknall R.C., Fraser W.D. Biochemical markers of bone turnover in seronegative spondyloarthropathy: relationship to disease activity. Br J Rheum. 36:1997;50-53
26. Toussirot E., Nguyen N.U., Dumoulin G., Regnard J., Wendling D. Insulin-like growth factor-1 and insulin-like binding protein-3 serum levels in ankylosing spondylitis. Br J Rheumatol. 37:1998;1172-1176
27. Toussirot E., Racadot E., Nguyen N.U., Dumoulin G., Wendling D. Absence of relation between TGFβ1 serum levels and bone mass in ankylosing spondylitis patients. Clin Exp Rheumatol. 18:2000;111
28. Szeijfeld V.L., Moniier-Faugere M.C., Bognar B.J., Ferraz M.B., Malluche B.J. Systemic osteopenia and mineralization defect in ankylosing spondylitis. J Rheumatol. 24:1997;683-688
29. Gough A., Lilley J., Eyre S., Holder R.L., Emery P. Generalized bone loss in patients with early rheumatoid arthritis. Lancet. 344:1994;23-27
30. Formiga F., Moga I., Nolla J.M., Pac M., Mitjavila F., Roig-Escofet D. Loss of bone mineral density in premenopausal women with systemic lupus erythematosus. Ann Rheum Dis. 54:1995;274-276
31. Maillefert J.F., Aho S., El Maghraoui A., Dougados M., Roux C. Changes in bone density in patients with ankylosing spondylitis: a 2 year follow-up study. Osteoporosis Int. 12:2001;605-609
32. Gratacos J., Collado A., Pons F., Osaba M., Sanmarti R., Roqué M., et al. Significant loss of bone mass in patients with early, active ankylosing spondylitis. A follow-up study. Arthritis Rheum. 42:1999;2319-2324
33. Toussirot E., Wendling D. L'ostéoporose de la spondylarthrite ankylosante. Presse Med. 25:1996;720-724
34. Toussirot E., Wendling D. Bone mass in ankylosing spondylitis. Clin Exp Rheumatol. 18:(Suppl 21):2000;S16-S20
35. Giltay E.J., van Schaardenburg D., Gooren L.J., Popp-Snijders C., Dijkmans B.A. Androgens and ankylosing spondylitis: a role in the pathogenesis? Ann New York Acad Sci. 876:1999;340-364
36. Armour K.E., Van'T Hof R.J., Grabowski P.S., Reid D.M., Ralston S.H. Evidence for a pathogenic role of nitric oxide in inflammation-induced osteoporosis. J Bone Miner Res. 14:1999;2137-2142
37. De Keyser F., Baeten D., Van den Bosch F., De Vos M., Cuvelier C., Mielants H., et al. Gut inflammation and spondyloarthropathies. Curr Rheumatol Rep. 4:2002;525-532
38. El Maghraoui A., Dougados M., Freneaux E., Chaussade S., Amor B., Breban M. Concordance between abdominal scintigraphy using technetium-99m hexamethylpropylene amine oxime-labelled leucocytes and ileocolonoscopy in patients with spondyloarthropathies and without clinical evidence of inflammatory bowel disease. Rheumatology. 38:1999;543-546
39. Maksymowych W.P., Jhangri G.S., Fitzgerald A.A., LeClercq S., Chiu P., Yan A., et al. A 6-month randomized, controlled, double-blind, dose-response comparison of intravenous pamidronate (60 versus 10 mg) in the treatment of nonsteroidal antiinflammatory drug-refractory ankylosing spondylitis. Arthritis Rheum. 46:2002;766-773
40. Brandt J., Haibel H., Cornely D., Golder W., Gonzalez J., Reddig J., et al. Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor α monoclonal antibody infliximab. Arthritis Rheum. 43:2000;1346-1352
41. Braun J., Sieper J. Anti-TNFα: a new dimension in the pharmacotherapy of the spondyloarthropathies? Ann Rheum Dis. 59:2000;404-406
42. Kruithof E., Van den Bosch F., Baeten D., Herssens A., De Keyser F., Mielants H., et al. Repeated infusions of infliximab, a chimeric anti-TNFa monoclonal antibody, in patients with active spondyloarthropathy: 1 year follow up. Ann Rheum Dis. 61:2002;207-212
43. Dernis E., Roux C., Breban M., Dougados M. Infliximab in spondylarthropathy. Influence on bone density. Clin Exp Rheumatol. 20:(Suppl 28):2002;S185-S186
44. Allali F., Breban M., Porcher R., Maillefert J.F., Dougados M., Roux C. Increase in bone mineral density of patients with spondyloarthropathy treated with anti-tumour necrosis factor alpha. Ann Rheum Dis. 62:2003;347-349
45. Bessant R., Keat A. How should clinicians manage osteoporosis in ankylosing spondylitis? J Rheumatol. 29:2002;1511-1519
46. Haibel H., Braun J., Maksymowych W.P. Bisphosphonates: targeting bone in the treatment of spondyloarthritis. Clin Exp Rheumatol. 20:(Suppl 28):2002;S162-S166